Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects

Autor: Miriam Ender, Matthias Riewald, Paolo Galli, Jerzy Madon, Reto A. Schuepbach
Přispěvatelé: University of Zurich, Schuepbach, R A
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Indazoles
Protein Conformation
Molecular Sequence Data
2720 Hematology
610 Medicine & health
030204 cardiovascular system & hematology
Cleavage (embryo)
Arginine
Transfection
Article
Antibodies
03 medical and health sciences
Structure-Activity Relationship
0302 clinical medicine
Thrombin
medicine
Staurosporine
Humans
Urea
Receptor
PAR-1

Amino Acid Sequence
Binding site
030304 developmental biology
0303 health sciences
Chemistry
HEK 293 cells
Endothelial Cells
Hematology
Molecular biology
Peptide Fragments
3. Good health
Cell biology
Protease-Activated Receptor 1
HEK293 Cells
10022 Division of Surgical Research
Cytoprotection
cardiovascular system
RNA Interference
Receptors
Thrombin

Binding Sites
Antibody

Signal transduction
10023 Institute of Intensive Care Medicine
medicine.drug
Protein C
Signal Transduction
Zdroj: Journal of thrombosis and haemostasis : JTH
Popis: Summary. Background: Activated protein C (aPC) mediates powerful cytoprotective effects through the protease-activated receptor-1 (PAR1) that translate into reduced harm in mouse injury models. However, it remains elusive how aPC-activated PAR1 can mediate cytoprotective effects whereas thrombin activation does the opposite. Objectives: We hypothesized that aPC and thrombin might induce distinct active conformations in PAR1 causing opposing effects. Methods: We analyzed antibody binding to, and cleavage and signalling of PAR1 in either endogenously expressing endothelial or overexpressing 293T cells. Results: In thrombin-cleaved PAR1 neither the tethered ligand nor the hirudin-like domain were available for anti-PAR1 ATAP2 and WEDE15 binding unless the tethered ligand was quenched. In contrast, aPC irreversibly prevented ATAP2 binding while not affecting WEDE15 binding. Reporter constructs with selective glutamine substitutions confirmed R41 as the only thrombin cleavage site in PAR1, whereas aPC preferentially cleaved at R46. Similarly, we report distinct cleavage sites on PAR3, K38 for thrombin and R41 for aPC. A soluble peptide corresponding to R46-cleaved PAR1 enhanced the endothelial barrier function and reduced staurosporine toxicity in endothelial as well as in 293T cells if PAR1 was expressed. Overexpression of PAR1 variants demonstrated that cleavage at R46 but not R41 is required for cytoprotective aPC signaling. Conclusions: We provide a novel concept on how aPC and thrombin mediate distinct effects. We propose that the enzyme-specific cleavage sites induce specific conformations which mediate divergent downstream effects. This unexpected model of PAR1 signaling might lead to novel therapeutic options for the treatment of inflammatory diseases.
Databáze: OpenAIRE